Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial

1. Trial Failure: Roche's TIGIT drug tiragolumab has failed another Phase 3 lung cancer trial, SKYSCRAPER-06, which compared tiragolumab plus Tecentriq and chemotherapy to Keytruda plus chemotherapy.
2. Worse Outcomes: The trial showed that patients receiving tiragolumab had worse outcomes, with a 33% higher risk of death and a 27% higher risk of progression or death compared to the control arm.
3. Impact on Skyscraper-01: The failure of SKYSCRAPER-06 raises doubts about the clinical significance of the Skyscraper-01 trial, which is still ongoing and has shown some positive signs in overall survival but failed on progression-free survival.
4. Comparison to Keytruda: The results suggest that Keytruda may be a more effective treatment than Tecentriq, and that tiragolumab does not add significant benefit to Tecentriq.
5. Future of TIGIT: The failure of tiragolumab in multiple trials raises questions about the viability of the TIGIT class of immune checkpoint inhibitors, which are being developed by several companies including Roche, Gilead, Merck, and GlaxoSmithKline.